Neuphoria Therapeutics Files 8-K on Financials
Ticker: NEUP · Form: 8-K · Filed: May 20, 2025 · CIK: 1191070
| Field | Detail |
|---|---|
| Company | Neuphoria Therapeutics Inc. (NEUP) |
| Form Type | 8-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
Neuphoria Therapeutics dropped an 8-K detailing its financial results. Check it out.
AI Summary
Neuphoria Therapeutics Inc. filed an 8-K on May 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company, previously known as Bionomics Limited/FI, is incorporated in Delaware and headquartered in Burlington, Massachusetts.
Why It Matters
This filing provides investors with an update on Neuphoria Therapeutics' financial performance and condition, which is crucial for assessing the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information beyond standard reporting requirements.
Key Players & Entities
- Neuphoria Therapeutics Inc. (company) — Registrant
- May 20, 2025 (date) — Date of Report
- Bionomics Limited/FI (company) — Former Company Name
- 100 Summit Dr, Burlington, Massachusetts 01803 (location) — Principal Executive Offices
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not provided in the provided text.
When was Neuphoria Therapeutics Inc. previously known as Bionomics Limited/FI?
The date of the name change from Bionomics Limited/FI to Neuphoria Therapeutics Inc. was September 20, 2002.
What is Neuphoria Therapeutics Inc.'s fiscal year end?
Neuphoria Therapeutics Inc.'s fiscal year ends on June 30.
What is the SIC code for Neuphoria Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Neuphoria Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for Neuphoria Therapeutics Inc.?
The principal executive offices are located at 100 Summit Dr, Burlington, Massachusetts 01803.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding Neuphoria Therapeutics Inc. (NEUP).